Showing 850 results
-
Media Release /Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + MekinistTafinlar + Mekinist combination also demonstrated…
-
Media Release /- 104 Week sub-analysis data from the Cosentyx Phase III FUTURE 1 trial in patients with psoriatic arthritis (PsA) presented at ACR 2015(1,2)- Patients receiving Cosentyx through 104 weeks maintained…
-
Media Release /- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and…
-
Media Release /- 104 Week sub-analysis data from the Cosentyx Phase III Measure 1 study in patients with ankylosing spondylitis (AS) presented at ACR 2015(1,2)- Two-year x-ray data from observational sub-analysis…
-
Media Release /- Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma- Successful technology transfer enabling commercial scale-up of CTL019 cell…
-
Media Release /Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will be…
-
Media Release /Following a heart failure hospitalization, 44% fewer patients treated with Entresto were readmitted for heart failure, and 36% fewer patients were readmitted for any cause, within 30 days compared to…
-
Media Release /- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications…
-
Media Release /- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements…
-
Media Release /- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on…
